

Riccardo Scotto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2480081/publications.pdf>

Version: 2024-02-01

52
papers

943
citations

430442

18
h-index

500791

28
g-index

53
all docs

53
docs citations

53
times ranked

1702
citing authors

#	ARTICLE	IF	CITATIONS
1	Disrupted Intestinal Microbiota and Intestinal Inflammation in Children with Cystic Fibrosis and Its Restoration with Lactobacillus GG: A Randomised Clinical Trial. PLoS ONE, 2014, 9, e87796.	1.1	182
2	Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitely Get a Role to Fusobacterium periodonticum?. Frontiers in Cellular and Infection Microbiology, 2021, 11, 625581.	1.8	59
3	Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opinion on Drug Safety, 2018, 17, 709-717.	1.0	55
4	Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity "LINA) Tj ETQq0 0 0 rgBT /Overlock 16 Tf 50 61	1.0	46
5	Immunocytometric analysis of COVID patients: A contribution to personalized therapy?. Life Sciences, 2020, 261, 118355.	2.0	32
6	Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. Reviews on Recent Clinical Trials, 2019, 14, 173-182.	0.4	30
7	Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial. Journal of Cystic Fibrosis, 2018, 17, 375-382.	0.3	28
8	Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis. International Journal of Infectious Diseases, 2017, 63, 23-29.	1.5	26
9	Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia. International Journal of Environmental Research and Public Health, 2021, 18, 2078.	1.2	24
10	Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience. International Journal of Environmental Research and Public Health, 2021, 18, 11399.	1.2	24
11	The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study. International Journal of Infectious Diseases, 2015, 36, 31-38.	1.5	23
12	Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study. Internal and Emergency Medicine, 2020, 15, 263-271.	1.0	23
13	<i>Pneumocystis jirovecii</i> pneumonia in an immunocompetent patient recovered from COVID-19. Infectious Diseases, 2021, 53, 382-385.	1.4	23
14	Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 123-126.	1.4	22
15	Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. Journal of Nephrology, 2019, 32, 763-773.	0.9	21
16	Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens. Open Forum Infectious Diseases, 2019, 6, ofz445.	0.4	21
17	Adherence to Guidelines for Management of Children Hospitalized for Acute Diarrhea. Pediatric Infectious Disease Journal, 2014, 33, 1103-1108.	1.1	20
18	Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs, 2016, 25, 557-572.	1.9	19

#	ARTICLE	IF	CITATIONS
19	Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. <i>New Microbiologica</i> , 2018, 41, 26-29.	0.1	18
20	Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage. <i>European Journal of Internal Medicine</i> , 2017, 46, e45-e47.	1.0	16
21	Successful treatment of post-surgical osteomyelitis caused by XDR <i>Pseudomonas aeruginosa</i> with ceftolozane/tazobactam monotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2678-2679.	1.3	16
22	Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study. <i>Sexual Health</i> , 2018, 15, 408.	0.4	16
23	Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC. <i>In Vivo</i> , 2019, 33, 177-182.	0.6	16
24	Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of <i>Clostridioides difficile</i> Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis. <i>Antibiotics</i> , 2022, 11, 183.	1.5	16
25	Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. <i>In Vivo</i> , 2017, 31, 695-700.	0.6	15
26	The therapeutic potential of new investigational hepatitis C virus translation inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1209-1214.	1.9	14
27	The role of curcumin in liver diseases. <i>Archives of Medical Science</i> , 2019, 15, 1608-1620.	0.4	14
28	Recommendations Concerning the First-Line Treatment of Children with Tuberculosis. <i>Paediatric Drugs</i> , 2016, 18, 13-23.	1.3	11
29	Chest CT in COVID-19 patients: Structured vs conventional reporting. <i>European Journal of Radiology</i> , 2021, 138, 109621.	1.2	10
30	How to manage children who have come into contact with patients affected by tuberculosis. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2015, 1, 1-12.	0.6	9
31	Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. <i>Journal of Neurology</i> , 2022, 269, 3301-3307.	1.8	9
32	Indications to Hospital Admission and Isolation of Children With Possible or Defined Tuberculosis. <i>Medicine (United States)</i> , 2015, 94, e2045.	0.4	8
33	Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 261-273.	0.9	8
34	SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience. <i>Frontiers in Medicine</i> , 2022, 9, 864865.	1.2	8
35	Asunaprevir for hepatitis C: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1631-1646.	1.0	6
36	The serum-ascites vitamin D gradient (SADG): A novel index in spontaneous bacterial peritonitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e57-e60.	0.7	6

#	ARTICLE	IF	CITATIONS
37	Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence. <i>Medicine (United States)</i> , 2020, 99, e18948.	0.4	6
38	Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 129-135.	0.4	6
39	Cytometric analysis of patients with COVID-19: what is changed in the second wave?. <i>Journal of Translational Medicine</i> , 2021, 19, 403.	1.8	5
40	Efficacy of the "first wave" Direct Acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort. <i>New Microbiologica</i> , 2019, 42, 94-100.	0.1	5
41	An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 395-397.	1.9	4
42	Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR <i>Pseudomonas aeruginosa</i> in patients with impaired renal function: a case series from a single-center experience. <i>Infection</i> , 2020, 48, 303-307.	2.3	4
43	Hepatitis C screening in the Emergency Department of a large hospital in southern Italy: results of a pilot study. <i>Infezioni in Medicina</i> , 2019, 27, 32-39.	0.7	4
44	Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 191-202.	2.0	3
45	Epidemiological and clinical features of syphilis in the 21st century: A seven-year observational retrospective study of outpatients. <i>Clinical Epidemiology and Global Health</i> , 2022, 16, 101100.	0.9	3
46	Recommendations for pediatric tuberculosis vaccination in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 644-650.	1.4	2
47	Monoclonal antibodies against <i>Clostridium difficile</i> infection in the pipeline. <i>Drugs of the Future</i> , 2014, 39, 693.	0.0	2
48	Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103814.	0.9	2
49	Factors Affecting Outcome of Tuberculosis in Children in Italy: An Ecological Study. <i>Advances in Experimental Medicine and Biology</i> , 2016, 973, 71-79.	0.8	1
50	Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life "Liver Network Activity"™ (LINA) cohort update results. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1057-1063.	1.4	1
51	Should SARS CoV-2 infection be considered an independent risk factor for <i>Pneumocystis jirovecii</i> pneumonia? Emerging data after two years of pandemic from a single center experience. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, .	0.4	1
52	Does compulsory vaccination limit personal freedom? Ethical issues. <i>Australasian Medical Journal</i> , 2018, 11, .	0.1	0